Impact of the Number of Anti-Thrombosis Agents in Hemodialysis Patients: BOREAS-HD2 Study

• Prif Awduron: Marenao Tanaka (Awdur), Norihito Moniwa (Awdur), Hirofumi Ohnishi (Awdur), Tomohisa Yamashita (Awdur), Masayuki Koyama (Awdur), Yufu Gocho (Awdur), Keitaro Nishizawa (Awdur), Yukishige Kimura (Awdur), Hirohito Sugawara (Awdur), Sayaka Murakami (Awdur), Yusuke Okazaki (Awdur), Masato Furuhashi (Awdur), Hideaki Yoshida (Awdur), Tetsuji Miura (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Karger Publishers, 2017-09-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Background/Aims: Relationships between the number of anti-thrombosis agents, clinical benefits and adverse events in hemodialysis (HD) patients are unclear. Methods: All patients on HD in 22 institutes (n = 1,071) were enrolled and followed up for 3 years. After exclusion of patients with missing da...